Cardiac angiosarcoma: a formidable challenge

Daniele Trombetti, Calogera Pisano, Maria Sabrina Ferrante, Laura Asta, Claudia Altieri, Paolo Nardi, Dario Buioni, Giovanni Ruvolo

Department of Cardiac Surgery, University of Tor Vergata, Rome, Italy

Kardiochirurgia i Torakochirurgia Polska 2023; 20 (1): 53-56

Primary cardiac angiosarcoma (AS) is a clinically rare (incidence of about 0.017%) and highly invasive cardiac tumor with an unfavorable prognosis. The general prognosis of patients with primary cardiac sarcoma is poor, with median overall survival which ranges from 9 to 27 months in recent case series [1]. Cases of primary cardiac angiosarcoma (PCAS) are extraordinarily rare but represent most cases of malignant cardiac cancer. PCAS originates from vascular endothelial cells or vascular endothelial cells that have differentiated from mesenteric cells. Much of the literature indicates that a majority of PCAS cases occur in the right atrium. Cardiac sarcomas usually present insidious symptoms in young and middle-aged patients. They generally have an unfavorable prognosis with an overall survival of between 6 and 12 months. The treatment of choice for these rare malignancies is a combination of surgical resection and radio- and/or chemotherapy [2]. However, in most cases, and in contrast to benign cardiac tumors, surgical resection still represents a palliative strategy for many patients with cardiac sarcomas. Therefore, rapid and accurate diagnosis is necessary and can confer a survival advantage on individual patients [3].

As this study was carried out in order to improve the management of primary cardiac angiosarcoma, local approval at the level of the surgical department was obtained prior to data collection and the patient signed the consent form for scientific purposes.

In April 2020, a 41-year-old patient was admitted to the Emergency Room of Tor Vergata University for dyspnea associated with chest tightness and vertigo. The echocardiography examination showed a round-shaped hyperechoic formation (6 × 4 cm) occupying all the left atrium until the inflow tract of the left ventricle with a large base of implantation in the anterior portion of the atrial septum (Figures 1 A–C). This mass engaged the mitral valve, resulting in severe steno-insufficiency (transvalvular medium gradient 27 mm Hg). A computed tomography (CT) raised the hypothesis of a PCAS (Figures 2 A–C). After a multidisciplinary clinical discussion, the patient was transferred to our Cardiac Surgery Unit for a cardiac operation. A standard longitudinal sternotomy was performed and the patient underwent cardiopulmonary bypass for exeresis of the mass. At the opening of the left atrium the mass adhered tenaciously to the atrial septum, the left auricle, the free wall of the left atrium and the anterior flap of the mitral valve. Despite the presence of tenacious adhesions of the mass to the atrial structures, it was possible to perform a total mass exeresis removing the atrial endocardium and mitral valve. We replaced the mitral valve with a Bicarbon Fitline mechanical prosthesis 25 mm. At the macroscopic examination the mass appeared bi-lobed, with a lardaceous consistency and a gray color. Histological examination evidenced a malignant mesenchymal neoplasm with spindle cells and necrotic areas associated with a severe inflammatory lympho-plasmacellular component. These findings confirmed an undifferentiated pleomorphic sarcoma. The postoperative course was uneventful and the patient was discharged on the 5th post-operative day. He immediately started a chemotherapy protocol with paclitaxel 150 mg/m² in a 3 weeks on/1 week off regimen and propranolol 40 mg three times daily associated with a moderate dose of radiotherapy of the chest. Two years’ follow-up showed no recurrence of pathology. He is still alive and in good health (Figures 3 A–E).

Primary tumors of the heart are extremely rare, and the majority are benign. PCAS is the most common primary malignant tumor of the heart [4]. It is a rare subgroup of soft tissue sarcomas, and is associated with a poor prognosis due to its aggressive nature and high rates of local recurrence and systemic metastases [5]. The rapid infiltrating growth of this tumor can lead to emergency clinical presentations including pericardial effusions, cardiac tamponade, and myocardial rupture [6]. The treatment of choice for these rare malignancies is a combination of surgical resection and radio- and/or chemotherapy. However, in most cases, and in contrast to benign cardiac tumors, surgical resection still represents a palliative strategy for many patients with cardiac sarcomas. An immediate diagnosis and quick treatment represent the only weapon to defeat this insidious disease, as we showed in this interesting case report. Several studies...
Cardiac angiosarcoma: a formidable challenge

Figure 1. Transesophageal echocardiogram images of the mass occupying all the left atrium (A, B) until the inflow tract of the left ventricle (C)

Figure 2. Computed tomography scan images (A, B) and reconstruction (C) of the mass in the left atrium
LETTER TO THE EDITOR

Figure 2. Cont. (C)

Figure 3. Intraoperative image of the mass in the left atrium (A), of the mass extraction (B) and of the two lobes of the mass (C–E)
have shown that when localized, surgical resection leads to the best chance of long-term survival [7–9]. However, surgery is often technically challenging, particularly since these tumors occur within the heart or in close proximity to the great vessels. Furthermore, the rapidly progressive nature of this disease can mean surgery is not an option for some patients. Given the aggressive nature of these tumors, combined modality therapies have emerged as a potential way to achieve better survival outcomes. There are several case reports and case series of patients treated with adjuvant radiotherapy, as well as neoadjuvant or adjuvant chemotherapy. Chemotherapy can shrink the tumor mass, allowing for radical surgery [10]. Various chemotherapeutic agents have been used, including paclitaxel, doxorubicin, ifosfamide, docetaxel, gemcitabine, cyclophosphamide, vincristine, and dacarbazine. In our opinion, this tumor is a formidable challenge that requires an experienced team of people ready to implement the most suitable therapeutic strategy and to ensure patients’ survival.

Disclosure

The authors report no conflict of interest.

References